Structures of several clinically relevant NUDT15 variants are discovered – paving the way for better cancer treatments
Recent research by a group of researchers from Sweden, the US, and the UK successfully developed a specific NUDT15 inhibitor, TH7755, that helped the group to obtain structures of clinically relevant NUDT15 variants: Arg139Cys, Arg139His, Val18Ile, and V18_V19insGlyVal. These insights allow further understandings of the structural basis of thiopurine intolerance in patients carrying these NUDT15